![FDA approves first chemotherapy and immunotherapy combination for non-small cell lung cancer](https://www.hoaallc.com/wp-content/uploads/2017/10/IMG_5215.jpeg)
The FDA recently granted accelerated approval for pembrolizumab in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-small cell lung cancer (non-squamous). This is the first approval to combine immunotherapy with chemotherapy in lung cancer. The trial compared standard chemotherapy to pembrolizumab along with standard chemotherapy in patients that… Read more »